<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1892">
  <stage>Registered</stage>
  <submitdate>28/02/2008</submitdate>
  <approvaldate>28/02/2008</approvaldate>
  <nctid>NCT00641641</nctid>
  <trial_identification>
    <studytitle>The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection</studytitle>
    <scientifictitle>An Open Label Study to Examine the Characteristics of HIV Decay Following Introduction of Combination Antiretroviral Therapy Including Raltegravir During Primary and Chronic HIV Infection</scientifictitle>
    <utrn />
    <trialacronym>PINT</trialacronym>
    <secondaryid>PINT01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Tenofovir + emtricitabine + raltegravir.

Experimental: antiretroviral therapy - tenofovir (TDF) + emtricitabine (FTC) as a fixed dose combination administered orally once per day and raltegravir (RAL) administered orally twice per day.


Treatment: drugs: Tenofovir + emtricitabine + raltegravir.
TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean Change From Baseline Plasma HIV RNA (Log Copies/mL) - change was calculated as the mean of 12 assessments minus the baseline value</outcome>
      <timepoint>12 times within 48 weeks.</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age at least 18 years.

          -  Provision of written, informed consent.

          -  Screening plasma HIV RNA &gt; 10,000 copies/mL.

          -  Screening CD4+ T lymphocyte count &gt; 100 x 10^6)/L.

          -  No previous antiretroviral therapy.

          -  Haemoglobin &gt; 115 g/L (female) or &gt; 130 g/L (male).

          -  Absolute neutrophil count &gt; 1 x 10^9/L.

          -  Platelet count &gt; 100 x 10^9/L

          -  Serum bilirubin &lt; 1.5 x ULN.

          -  Serum alkaline phosphatase &lt; 3 X ULN.

          -  Serum aspartate aminotransferase (AST) &lt; 3 X ULN.

          -  Serum alanine aminotransferase (ALT) &lt; 3 X ULN.

          -  Creatinine clearance &gt; 50mL/min (Creatinine clearance (mL/min) =140 - age x weight
             creatinine Multiply the result by 1.2 for men).

        Cohort A: Primary HIV infection:

        Documented acute or early infection diagnosed by:

        Acute infection:

        &lt; 3 bands on Western Blot and any one of: i. positive p24 antigen ii. positive proviral DNA

        Early infection:

        i. Positive detuned or BED ELISA result OR ii. Previously negative serology within 6 months
        of confirmed positive serology.

        Cohort B: Chronic HIV infection:

        Documented HIV-infection of at least 12 months duration.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnancy or breastfeeding.

          -  Receipt of investigational products within 1 month of study entry.

          -  Receipt of any of the following within 6 months of study entry:

               -  interferon alpha or gamma

               -  oral corticosteroids (inhaled or topical corticosteroids are permitted)

               -  cyclosporin

               -  alkylating agents

               -  other immunosuppressive agents

               -  rifampin

               -  phenytoin

               -  phenobarbital

          -  Documented genotypic (IAS 2007) resistance to tenofovir or emtricitabine from any HIV
             drug resistance test.

          -  Any medications contraindicated with Truvada or raltegravir.

          -  Significant intercurrent illnesses apart from HIV infection such as viral hepatitis
             (diagnosed by core hepatitis B antigen and/or positive hepatitis B PCR or positive
             hepatitis C PCR) or any other condition which in the opinion of the investigator would
             compromise participation in the study.

          -  History of non-traumatic osteoporotic fracture.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>16</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>St Vincent's Hospital - Darlinghurst, Sydney</hospital>
    <hospital>407 Doctors - Sydney</hospital>
    <hospital>Holdsworth House Medical Practice - Sydney</hospital>
    <hospital>Taylor Square Private Clinic - Sydney</hospital>
    <postcode>2010 - Darlinghurst, Sydney</postcode>
    <postcode>2010 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Kirby Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Merck Sharp &amp; Dohme Corp.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to measure the decay characteristics of HIV in the blood of
      patients after taking a combination of anti-HIV drugs, which includes a new class of anti-HIV
      drug, an integrase inhibitor. This study explores how this new combination of therapy reduces
      virus in various compartments of the body and immune system.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00641641</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Anthony Kelleher, MBBS (Hons) PhD, FRACP, FRCPA</name>
      <address>Kirby Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>